Reading IRON? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IRON free→Reading IRON? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IRON free→QuarterlyIQ Insights · IRON
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Costs Associated with Exit or Disposal Activities. On February 26, 2026, the board of directors of Disc Medicine, Inc. (the “Company”) approved, and management began implementing, a restructuring plan (the “Restructuring Plan”) to better align the Company’s workforce with its near-term strategic priorities following the receipt of a complete response letter from the U.S. Food and Drug Administration (“FDA”) on February 13, 2026 with respect to the Company’s New Drug Application for bitopertin…
of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Regulation FD Disclosure. On February 17, 2026, Disc Medicine, Inc. (the "Company") will host a previously-announced conference call at 8:00 AM ET to discuss the Complete Response Letter issued by the U.S. Food and Drug Administration on February 13, 2026 with respect to the Company's New Drug Application for bitopertin as a treatment for patients with erythropoietic protoporphyria. An archived webcast will be available following the call for 30 days on the Events & Presentations section of t…
Other Events. On February 13, 2026, the Company received a CRL from the FDA for the Company’s NDA for bitopertin as a treatment for patients with EPP.
Regulation FD Disclosure. On February 13, 2026, Disc Medicine, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") for the New Drug Application ("NDA") for bitopertin as a treatment for patients with erythropoietic protoporphyria ("EPP"). A copy of the press release and a copy of the CRL are attached as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and are incorpor…
Results of Operations and Financial Condition. On January 12, 2026, Disc Medicine, Inc. (the “Company”) issued a press release announcing, among other things, that its preliminary unaudited cash, cash equivalents and marketable securities as of December 31, 2025 were approximately $791 million. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The Company has not yet completed its year-end financial close process for the year ended December 31, 2025.…
of this Current Report on Form 8-K shall be deemed to be furnished and not filed: Exhibit No. Description 99.1 Press release issued by Disc Medicine, Inc. on November 6, 2025, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DISC MEDICINE, INC. Date:…
Entry into a Material Definitive Agreement. On October 20, 2025, Disc Medicine, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC, Leerink Partners LLC, Morgan Stanley & Co. LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters listed on Schedule I thereto (the “Underwriters”) and AI DMI LLC, as a selling stockholder (the “Selling Stockholder”), related to an underwritten offering (the “Offering”) (i) by the…
Other Events. On October 20, 2025, the Company issued a press release announcing the commencement of the Offering. On October 21, 2025, the Company issued a press release announcing that it had priced the Offering. Copies of these press releases are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated by reference herein. Cautionary Statement Regarding Forward-Looking Statements This Current Report on Form 8-K contains “forward-looking statements” within the me…
Results of Operations and Financial Condition. On October 20, 2025, Disc Medicine, Inc. (the “Company”) announced that its preliminary unaudited cash, cash equivalents and marketable securities as of September 30, 2025 were approximately $615.9 million. The Company has not yet completed its quarter-end financial close process for the quarter ended September 30, 2025. This estimate of the Company’s cash, cash equivalents and marketable securities as of September 30, 2025 is preliminary, has no…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 3, 2025, Mona Ashiya, Ph.D., a Class I member of the Board of Directors (the “Board”) of Disc Medicine, Inc. (the “Company”), notified the Company of her resignation from the Board, effective October 3, 2025. Dr. Ashiya was a member of the Compensation Committee and the Nominating and Corporate Governance Committee of the Board and, by r…
of this Current Report on Form 8-K shall be deemed to be furnished and not filed: Exhibit No. Description 99.1 Press release issued by Disc Medicine, Inc. on August 7, 2025, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DISC MEDICINE, INC. Date: Au…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 9, 2025, the Board of Directors (the “Board”) of Disc Medicine, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Nadim Ahmed as a director, effective as of July 14, 2025 (the “Effective Date”). Mr. Ahmed has been designated as a class I director to serve in accordance w…
of this Current Report on Form 8-K shall be deemed to be furnished and not filed: Exhibit No. Description 99.1 Press release issued by Disc Medicine, Inc. on May 7, 2025, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DISC MEDICINE, INC. Date: May 7…
of this Current Report on Form 8-K shall be deemed to be furnished and not filed: Exhibit No. Description 99.1 Press Release issued by Disc Medicine, Inc. on February 27, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DISC MEDICINE, INC. Date: Februar…
Entry into a Material Definitive Agreement. On January 22, 2025, Disc Medicine, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC, Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co. as representatives of the several underwriters listed on Schedule I thereto (the “Underwriters”), related to an underwritten offering (the “Offering”) of (i) 3,918,182 shares of common stock of the Company, par valu…
Other Events. On January 21, 2025, the Company issued a press release announcing the Offering. On January 22, 2025, the Company issued a press release announcing that it had priced the Offering. Copies of these press releases are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated by reference herein. Cautionary Statement Regarding Forward-Looking Statements This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private…
Other Events. On January 21, 2025, the Company announced positive feedback from its Type C meeting with the FDA to discuss the APOLLO post-marketing confirmatory trial for bitopertin in EPP and XLP. The meeting resulted in alignment on the design of the APOLLO post-marketing confirmatory trial. Key features include: • Co-primary endpoints of average monthly total time in sunlight without pain between 10:00 and 18:00 during the last month of the 6-month treatment period and percent change from…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.